- Home
- Search Results
Search Results
Filter :
FILTER BY keyword:
FILTER BY author:
- Abdulqadir J. Nashwan [1]
- Ahmed A. Karawia [1]
- Ashraf T. Soliman [1]
- Doaa H. Ahmed [1]
- Fateen Ata [1]
- Fatima Iqbal [1]
- Kamran Mushtaq [1]
- Mohamed A. Yassin [1]
- Mohammadshah I. Gul [1]
- Mohammed E. Elhadi [1]
- Mohammed N. Seijari [1]
- Mouhammad J. Alawad [1]
- Muhammad Abubakar [1]
- Samer J. Kaspo [1]
- Yousef M. Hailan [1]
- [+] More [-] Less
FILTER BY date:
FILTER BY language:
FILTER BY content type:
FILTER BY publication:
FILTER BY affiliation:
- Clinical Pharmacy Department, Communicable Diseases Center, Doha, Qatar [1]
- Clinical Pharmacy Department, Hamad Medical Corporation, Doha, Qatar [1]
- Department of Gastroenterology and Hepatology Hamad Medical Corporation, Doha Qatar Email & ORCID ID: [email protected] & https://orcid.org/0000-0001-7121-8574 [1]
- Department of Hematology and Oncology National Center for Cancer care and research (NCCCR), Doha, Qatar [1]
- Department of Internal Medicine, Hamad Medical Corporation, Doha, Qatar [1]
- Department of Paediatrics. Hamad Medical Corporation (HMC), Doha, Qatar [1]
- Harvard TH Chan School of Public Health, Boston, USA [1]
- Hematology Lab, Hamad Medical Corporation, Doha, Qatar [1]
- Nursing Department, Hamad Medical Corporation, Doha, Qatar [1]
- [+] More [-] Less
FILTER BY article type:
FILTER BY access type:
Hematologic Outcomes of COVID-19 Patients with and without G6PD Deficiency: A Comparative Study
Introduction: Patients with multiple comorbidities who have coronavirus disease 2019 (COVID-19) have high morbidity and mortality. Glucose-6-phosphate dehydrogenase (G6PD) deficiency has been shown to have an enhanced effect on coronavirus in an earlier study.
Methods: We conducted this comparative observational study to evaluate the effects of COVID-19 disease on G6PD deficiency based on the hematologic parameters COVID-19-related hospitalizations and mortality in the state of Qatar between January 2020 and May 2020 at four designated COVID-19 facilities. We identified 41 patients with G6PD deficiency who had documented COVID-19 infection. We compared the results with 241 patients with COVID-19 infection who tested negative for G6PD deficiency.: Results: Comparing the COVID-19 positive G6PD deficient with COVID-19 positive G6PD normal activity showed that G6PD normal group had higher white blood cell count (WBC) absolute neutrophil count (ANC) lymphocytes eosinophils and monocytes counts versus the G6PD deficient group (p < 0.001).
Conclusions: When compared with COVID-19 patients with normal G6PD patients with COVID-19 infection and G6PD deficiency had lower total WBC ANC lymphocyte monocyte and eosinophil counts. However no evidence of increased hemolysis thrombosis morbidity or mortality was observed in COVID-19 patients with G6PD deficiency.